Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has commenced dosing the next cohort of human participants with RECCE® 327 (R327) at 3,000mg intravenously at a fast infusion rate of 20 minutes in its Phase I/II UTI/urosepsis clinical trial.
The company is exploring multiple infusion times; 15-mins, 20-mins, 30-mins, 45-mins and 1-hour at 3,000mg, which is viewed as R327’s optimal dosing therapeutic window.
Recce established that the dose of 3,000mg — administered at varying infusion times between 15 and 60 minutes — has been proven to be safe in participants.
The remaining participants are to be dosed over the coming days, while the independent safety committee has unanimously cleared the next clinical intravenous (I.V.) dosing.
Potential to treat millions worldwide
Recce CEO James Graham said, "We're pleased to continue advancements within and surrounding our R327 clinical trials.
"The additional infusion time at 3,000mg over 20 minutes highlights a compelling safety profile with the potential to treat the millions of patients worldwide that suffer from UTI/urosepsis each year.”
In a parallel clinical program, R327 applied topically against diabetic foot ulcer infections recently demonstrated its efficacious potential against a broad range of antibiotic-resistant infections.
The efficacious potential of R327 via I.V. administration will only be made available at completion of this human clinical trial in line with study protocol.